Trend in medical expenditures for patients with kidney diseases: An analysis from a tertiary hospital in Beijing

  • Shu-hong BI ,
  • Zi-fan LI ,
  • Tao WANG ,
  • Yue WANG ,
  • Chen ZHANG ,
  • Hong JI ,
  • Ju SHI
Expand
  • 1. Division of Nephrology, Peking University Third Hospital, Beijing 100191, China
    2. School of Economics, Peking University, Beijing 100871, China
    3. Data Center, Peking University Third Hospital, Beijing 100191, China

Received date: 2019-06-12

  Online published: 2021-02-07

Supported by

National Natural Science Foundation of China(81100522);Key Project of Peking University Third Hospital(Y78436-05)

Abstract

Objective: To investigate trends in hospitalization expenditures in adults with kidney disease, to analyze the time pattern of outpatient and inpatient medical expenditures for patients with kidney diseases, and to support the health care reform by exploring the causes.Methods: Medical expenditure data for kidney disease patients aged ≥18 years from the outpatient and in-patient data of the information center in the Grade?A tertiary hospital in Beijing, China from January 1, 2012, to December 31, 2017, were retrospectively analyzed. It provided descriptive evidence on the time patterns of expenditures per visit and capita, and potential influencing factors of the time changes were further explored.Results: It was found that medical expenditures had increased rapidly from 2012 to 2017. The result showed that the average outpatient expenditure per capita for kidney disease patients was 4 598 yuan in 2012, with an increasing tendency to 11 536 yuan in 2017. There was an obvious increase in the average number of visits (per year) from 3.94 in 2012 to 9.11 in 2017. Meanwhile, the mean inpatient expenditures per capita had an increasing tendency from 323 753 yuan in 2012 to 45 904 yuan in 2017. There was also an increase of mean inpatient expenditures per admission from 27 184 yuan in 2012 to 34 933 yuan in 2017, with a similar number of admissions over the 6 years. The increases in outpatient and inpatient expenditures per capita were driven by different reasons. The increase in outpatient expenditures per capita was driven by the increase of patient visits, while the increase in inpatient expenditures per capita was driven by the increase of the expenditures per admission. Also, drug and medical materials were the two categories that had the largest contribution to the inpatient expenditures. Drug expenses were the highest one, with an average of 12 524 yuan per visit in 2017, accounting for 32.4% of the average total expenditure in that year, while the average cost of consumables was 9 215 yuan, accounting for 23.9%.Conclusion: The increase of outpatient expenditures per capita was related to the increase of patient visits. Meanwhile, the growth of drug and consumable costs contributed to the total increase in the total inpatient healthcare costs. It is necessary to increase the proportion of treatment costs and medical service fees in the total expenditure.

Cite this article

Shu-hong BI , Zi-fan LI , Tao WANG , Yue WANG , Chen ZHANG , Hong JI , Ju SHI . Trend in medical expenditures for patients with kidney diseases: An analysis from a tertiary hospital in Beijing[J]. Journal of Peking University(Health Sciences), 2021 , 53(1) : 215 -219 . DOI: 10.19723/j.issn.1671-167X.2021.01.033

References

[1] GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018,392(10159):1859-1922.
[2] Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives[J]. Lancet, 2013,382(9888):260-272.
[3] Wang V, Vilme H, Maciejewski ML, et al. The economic burden of chronic kidney disease and end-stage renal disease[J]. Semin Nephrol, 2016,36(4):319-330.
[4] 陈正祥, 程晓明, 李冀男, 等. 杭州市终末期肾病血液透析患者疾病经济负担研究[J]. 中国卫生经济, 2005,24(6):44-47.
[5] 肖月, 隋宾艳, 赵琨. 我国终末期肾病现状及透析技术的应用、费用及支付情况分析[J]. 中国卫生政策研究, 2011,4(5):29-33.
[6] 于洋, 王芝芳, 张希玉, 等. 威海市 2009 年终末期肾病疾病负担研究[J]. 中国卫生统计, 2013,30(2):272-274.
[7] 祝菁菁, 范文君, 黄韻宇, 等. 我国2 型糖尿病及糖尿病肾病的经济负担现状[J]. 中国卫生经济, 2013,32(4):32-34.
[8] 杜晔, 孟群. 我国慢性肾脏病防治政策及策略研究:基于卫生经济学视角[J]. 中国卫生政策研究, 2018,11(7):78-83.
[9] Eriksson JK, Neovius M, Jacobson SH, et al. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden[J]. BMJ Open, 2016,6(10):e012062.
[10] Small C, Kramer HJ, Griffin KA, et al. Non-dialysis dependent chronic kidney disease is associated with high total and out-of-pocket healthcare expenditures[J]. BMC Nephrol, 2017,18(1):3.
[11] Kerr M, Bray B, Medcalf J, et al. Estimating the financial cost of chronic kidney disease to the NHS in England[J]. Nephrol Dial Transplant, 2012, 27(Suppl 3): iii73-iii80.
[12] Ahlawat R, Tiwari P, D’Cruz S. Direct cost for treating chronic kidney disease at an outpatient setting of a tertiary hospital: evidence from a cross-sectional study[J/OL]. Value Health Reg Issues, 2017(2017-05-12)[2019-06-01]. https://doi.org/10.1016/j.vhri.2016.10.003.
[13] Anutrakulchai S, Mairiang P, Pongskul C, et al. Mortality and treatment costs of hospitalized chronic kidney disease patients between the three major health insurance schemes in Thailand[J]. BMC Health Serv Res, 2016,16(1):528.
Outlines

/